182 related articles for article (PubMed ID: 29113203)
1. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
Wang Y; Yi C; Wang Y; Li H; Li B; Wang D; Du J; Liu L; Wang X
Oncol Lett; 2017 Nov; 14(5):5743-5752. PubMed ID: 29113203
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
Li M; Wang Z; Guo J; Liu J; Li C; Liu L; Shi H; Liu L; Li H; Xie C; Zhang X; Sun W; Fang S; Bi X
Onco Targets Ther; 2014; 7():1653-61. PubMed ID: 25285015
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
4. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].
Wang X; Liu Y; Huang JX; Lu P; Ba Y; Wu L; Bai YX; Zhang S; Feng JF; Cheng Y; Li J; Wen L; Yuan XL; Ma CW; Hu CH; Fan QX; Xu BH; Huang J
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1177-1182. PubMed ID: 34794220
[No Abstract] [Full Text] [Related]
6. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.
Liu XH; Lu J; Duan W; Dai ZM; Wang M; Lin S; Yang PT; Tian T; Liu K; Zhu YY; Zheng Y; Sheng QW; Dai ZJ
J Cancer; 2017; 8(4):691-703. PubMed ID: 28367249
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
9. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
[TBL] [Abstract][Full Text] [Related]
11. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L
Med Oncol; 2013; 30(3):630. PubMed ID: 23783485
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Peng H; Duan Z; Pan D; Wen J; Wei X
Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
[TBL] [Abstract][Full Text] [Related]
13. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.
Xiao XG; Xia S; Zou M; Mei Q; Zhou L; Wang SJ; Chen Y
Onco Targets Ther; 2015; 8():3575-83. PubMed ID: 26664141
[TBL] [Abstract][Full Text] [Related]
14. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
[TBL] [Abstract][Full Text] [Related]
15. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
[TBL] [Abstract][Full Text] [Related]
16. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Li H; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276
[TBL] [Abstract][Full Text] [Related]
17. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Han FF; Guo CL; Yu D; Zhu J; Gong LL; Li GR; Lv YL; Liu H; An GY; Liu LH
Cancer Chemother Pharmacol; 2014 Apr; 73(4):779-88. PubMed ID: 24519753
[TBL] [Abstract][Full Text] [Related]
18. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer.
Zhou CF; Ma T; Su Y; Ye ZB; Ji J; Yu YY; Zhang J; Liu BY; Zhu ZG
Anticancer Agents Med Chem; 2013 Feb; 13(2):235-41. PubMed ID: 22934695
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
